Clinical trials recruiting for Hepatocellular carcinoma
51
Recruiting trials
29
US states with sites
23
Countries
4%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 9 |
| Texas | 7 |
| Florida | 4 |
| Michigan | 4 |
| New York | 4 |
| Colorado | 3 |
| Ohio | 3 |
| Pennsylvania | 3 |
| Missouri | 2 |
| New Jersey | 2 |
| Rhode Island | 2 |
| Utah | 2 |
Top cities
Houston, Texas 6San Antonio, Texas 5Grand Rapids, Michigan 3New York, New York 3Pittsburgh, Pennsylvania 3San Francisco, California 3Aurora, Colorado 2Cleveland, Ohio 2Denver, Colorado 2Fairfax, Virginia 2
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Multicenter Cancer Biospecimen Collection Study
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
- A Study of ZW251 in Participants With Advanced Solid Tumors
- A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Antiviral Therapy for Patients With Liver Cancer After Surgery
- Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
- CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
- Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
- Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
- Evaluating Novel Therapies in ctDNA Positive GI Cancers
- First in Human Study of SIM0610 in Solid Tumors
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- IDOV-Immune for Advanced Solid Tumors
- Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- JMT106 Injection in the Treatment of Advanced Solid Tumors
- Liver Cancer Disparities in American Indian and Alaska Native Persons
- Liver Disease and Other Systemic Diseases
- Liver Embolization Approaches for Tumor Management
- Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Personalized DC Vaccine for Postoperative Cancer
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
- Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC
- Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
- Relevance of Sarcopenia in Advanced Liver Disease
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- TARGETed Therapy Drug MONITOring in DIGestive Oncology
- TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- The European NAFLD Registry
- The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Related conditions
Trials recruiting for Hepatocellular carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Colorectal cancer 1359Pancreatic cancer 870Renal cell carcinoma 28Melanoma 487Breast cancer 2239Non-small cell lung cancer 507Gastric cancer 91Ovarian cancer 118Hepatitis B 147
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Hepatocellular carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.